PTCT News and Press, PTC Therapeutics Inc. From 03/28/24

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire - First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J. , March 28, 2024 /PRNewswire/ --&#...

PTC Therapeutics Provides Key Regulatory Updates PR Newswire - BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J...

2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...

2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...

2024-03-04 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire – 34% year-over-year growth in 2023 total revenue – – Global filings of sepiapterin remain on track with first submission of the ...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast c...

2024-02-12 16:46:59 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Q4 2023 Earnings Preview Biogen scraps Aduhelm,...

2024-02-11 18:00:00 ET Summary PTC Therapeutics has a diverse portfolio and pipeline of drugs, including a broader DMD treatment. The company has not fully expanded its revenue-generating products geographically and is in the process of making the necessary submissions to do so. ...